Tip 2 diyabet mellitusta demans biyobelirteçlerinin düzeyi

Year 2023, Volume: 48 Issue: 3, 825 - 832, 30.09.2023

Lütfiye Özpak , Murat Şahin , İbrahim Seyfettin Çelik , Bekir Mehmet Kelleci , Mustafa Çelik

https://doi.org/10.17826/cumj.1311596

Abstract

Amaç: Yaşlanan dünyanın bir hastalığı olan, Alzheimer hastalığı ve kanserdeki metastaz gibi, sistematik bir şekilde yayılarak doku ve organ hasarına neden olan Tip 2 diyabetin, etiyolojisinin aydınlatılması çok önemlidir. Bu çalışmada Alzheimer patogenezinde biyomarker olarak kullanılan belirteçlerin, diyabet patogenezinde etkili olup olmadığını incelemeyi amaçladık.
Gereç ve Yöntem: Çalışmamıza, 30 tip 2 diyabetli, minimental test sonucu demans riski taşıyan 30 tip 2 diyabetli birey ve 50-70 yaş arası 28 sağlıklı birey dahil edilerek plazma örneklerinden, beyin kaynaklı nörotrofik faktör (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) düzeyleri ölçüldü.
Bulgular: Demans riski yüksek olan diyabet grubu (MMSE < 24) ile diğer gruplar arasında Tau ve FABP7 düzeylerinde anlamlı bir fark bulunurken DYRK1A ve BDNF düzeylerinde anlamlı bir fark bulunmamıştır.
Sonuç: Bu biyobelirteçler T2D'li ve demans riski taşıyan hastalarda daha pahalı ve invaziv tanı yöntemlerine başvurmadan önce Alzheimer hastalığını teşhis etmek için kullanılabilir.

Keywords

Diabetes mellitus Tip 2, alzheimer hastalığı, beyin kaynaklı nörotrofik faktör, tau proteini, yağ asidi bağlayıcı protein 7, protein serin-treonin kinazlar

Supporting Institution

Kahramanmaraş Sütçü İmam Üniversitesi Bilimsel Araştırma Projeleri Birimi

Project Number

2020/6-25 M

Thanks

Kahramanmaraş Sütçü İmam Üniversitesi Bilimsel Araştırma Projeleri Birimine teşekkür ederiz.

The level of dementia biomarkers in type 2 diabetes mellitus

Abstract

Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes.
Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples.
Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels.
Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.

Keywords

Diabetes Mellitus Type 2, Alzheimer’s Disease, brain-derived neurotrophic factor, Tau protein, fatty acid- binding proteins 7, protein serin-threonine kinases

Project Number

2020/6-25 M

References

• Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Làszló F et al. Beta-amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010;31:1503-15.
• Wijesekara N, Gonçalves RA, De Felice FG, Fraser PE. Impaired peripheral glucose homeostasis and alzheimer's disease. Neuropharmacology. 2018;136:172-81.
• Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-8.
• Rozanska O, Uruska A, Zozulinska-Ziolkiewicz D. Brain-derived neurotrophic factor and diabetes. Int J Mol Sci. 2020;21:841.
• Deboever E, Fistrovich A, Hulme C, Dunckley T. The Omnipresence of DYRK1A in human diseases. Int J Mol Sci. 2022;23:9355.
• Jaiswal S, Mishra S, Torgal SS, Shengule S. Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats. Life Sci. 2018;207:364-71.
• Islam A, Kagawa Y, Miyazaki H, Shil SK,Umaru BA, Yasumoto Y et al. FABP7 protects astrocytes against ROS toxicity via lipid droplet formation. Mol Neurobiol. 2019;56:5763-79.
• Yasumoto Y, Miyazaki H, Ogata M, Kagawa Y, Yamamoto Y, Islam A et al. Glial fatty acid-binding protein 7 (FABP7) regulates neuronal leptin sensitivity in the hypothalamic arcuate nucleus. Mol Neurobiol. 2018;55:9016-28.
• Güngen C, Ertan T, Eker E, Yaşar R. Standardize mini mental test’in türk toplumunda hafif demans tanısında geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi. 2002;13:273-81.
• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
• Janel N, Alexopoulos P, Badel A, Lamari F, Camproux AC, LagardeJ et al. Combined assessment of DYRK1A, BDNF, and homocysteine levels as a diagnostic marker for alzheimer's disease. Transl Psychiatry. 2017;7:e1154.
• Krabbe KS, Nielsen AR, Krogh-Madsen RP, Rasmussen P, Erikstrup C, Fischer CP et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431-8.
• Laske C , Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E et al. Stage-dependent BDNF serum concentrations in Alzheimer’s disease. J Neural Transm. 2006;113:1217-24.
• Duan W, Guo Z, Jiang H, Ware M, Mattson MP. Reversal of behavioral and metabolic abnormalities, and ınsulin resistance syndrome, by dietary restriction in brain-derived neurotrophic factor. Endocrinology. 2003;144:2446–53.
• Świątoniowska-Lonc N, Polański J, Tański W, Jankowska-Polańska B. Impact of cognitive ımpairment on adherence to treatment and self-care in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2021;14:193–203.
• Munshi MN. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care. 2017;40:461-7.
• Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the accord trial. Diabetes Care. 2012;35:787-93.
• Rachdi L, Kariyawasam D, Guez F, Aiello V, Arbones ML, Janel N et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia. 2014;57:960–9.
• Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet. 2021;53:143-6.
• Needham H, Torpey G, Flores CC, Davis CJ, Vanderheyden VM, Gerstner JR. A Dichotomous role for FABP7 in sleep and alzheimer's disease pathogenesis: a hypothesis. Front Neurosci. 2022;16:798994.
• Movassat J, Delangre E, Liu J, Gu Y, Janel N. Hypothesis and theory: circulating alzheimer's-related biomarkers in type 2 diabetes. ınsight from the goto-kakizaki rat. Front Neurol. 2019;10:649.
• Teunissen CE, Veerhuis R, De Vente J, Verhey FR, Vreeling F, van Boxtel MP et al. Brain-specific fatty acid-binding protein is elevated in the serum of patients with dementia-related diseases. Eur J Neurol. 2011;18:865-71.
• Yang H, Oh CK, Amal H, Wishnok JS, Lewis S, Schahrer E et al. Mechanistic insight into female predominance in alzheimer's disease based on aberrant protein S-nitrosylation of C3. Sci Adv. 2022;8:eade0764.
• Hamzé R, Delangre E, Tolu S, Moreau M, Janel N, Bailbé D et al. Type 2 diabetes mellitus and alzheimer's disease: shared molecular mechanisms and potential common therapeutic targets. Int J Mol Sci. 2022;23:15287